Abram, Julia
Spraider, Patrick http://orcid.org/0000-0002-1605-6696
Wagner, Julian
Putzer, Gabriel
Ranalter, Manuela
Rinner, Sarah
Lindner, Andrea Katharina
Glodny, Bernhard
Hell, Tobias
Barnes, Tom
Enk, Dietmar
Martini, Judith
Funding for this research was provided by:
HORIZON EUROPE European Institute of Innovation and Technology (961787)
Article History
Received: 30 October 2023
Accepted: 23 February 2024
First Online: 7 March 2024
Declarations
:
: This study was approved by the Institutional Animal Care and Use Committee of the Medical University of Innsbruck and the Austrian Ministry of Science, Research and Economy (Protocol No.: BMBWF-V/3b 2020-0.363.123). The study was carried out at the Experimental Research Unit of the Department of Anesthesia and Intensive Care Medicine at the Medical University of Innsbruck and was performed in accordance with EU regulations for animal experimentation (EU-Directive 2010/63 of the European Parliament and the European Council); reporting is in accordance with current ARRIVE 2.0 guidelines [CitationRef removed].
: Not applicable.
: TB has patent applications on calculating and displaying dissipated energy and differentiating airway and tissue resistance. DE represents the inventor of EVA and FCV technology (Ventrain, Tritube, Evone), has royalties for EVA and FCV technology (Ventrain, Tritube, Evone), has patent applications on minimising dissipated energy and on calculating and displaying dissipated energy and differentiating airway and tissue resistance. All other authors have no conflicts of interest to declare.